Physician
Infectious Disease
Dr. Anthony J. Japour, MD
|
|
Give Review
Anthony J. Japour is an expert in the field of Infectious Disease. He attended Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine has a rank of 19 in research and a 29 in primary care Doctor Anthony J. Japour, MD is also a published MD. He has 40 paper published. The most recent paper is: Selective vertical transmission of HIV-1 antiretroviral resistance mutations. Anthony Japour accepts Medicare payments and is registered with Medicare.gov.
Publications
- Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection.
- Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type...
- Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
- Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors.
- Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral...
- Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
- Measurement of HIV-1 RNA in clinical practice: an initial management algorithm.
- A virologist's view from Vancouver.
- Antiretroviral drug resistance.
- ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
- The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Gr...
- HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmissio...
- A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resist...
- Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
- Selective vertical transmission of HIV-1 antiretroviral resistance mutations.
- ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
- Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Tria...
- Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.
- The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.
- Insertions into the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase reveal a role for fingers subdomain in processive polymerization.
- Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosid...
- Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). ...
- Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.
- Determination of HIV-1 susceptibility to reverse transcriptase (RT) inhibitors by a quantitative cell-free RT assay.
- Standardized peripheral blood mononuclear cell culture assay for zidovudine susceptibility testing of clinical human immunodeficiency virus type 1 isolates: effect of ...
- A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Gr...
- Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (...
- Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therap...
- The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. ...
- Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Cl...
- Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The R...
- Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.
- Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resista...
- Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates.
- Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AI...
- Vitamin K-dependent proteins and anticonvulsant medication.
- Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization.
- A rapid, direct test for zidovudine susceptibility in clinical isolates of human immunodeficiency virus type 1 (HIV-1) from infected children.
- Herpes virus infections, HIV, and disease progression. Wait and see.
Schools
Northwestern University The Feinberg School Of Medicine
Mt Auburn Hospital
Harvard Med School
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Education
-
Northwestern University Feinberg School of Medicine
Drug Facts
| NPI NUMBER | 1285723858 | |
| NPPES Provider LastName | JAPOUR | |
| NPPES Provider FirstName | ANTHONY | |
| NPPES Provider ZIPCode | 331397309 | |
| NPPES Provider State | FL | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 348.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285723858 |
| Last Name Of The Provider | JAPOUR |
| First Name Of The Provider | ANTHONY |
| View All |
Similar Doctors
|
|
Dr. Stephen A. Kotzen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Juan Querol, MD
This Doctor is OpenDoctor Recommended.
|